Federal Acts, Pharmacy Laws, Amendments

What are Federal drug related acts, prescription regulations and amendments?

Drug-related acts are laws and prescription regulations developed over time to ensure the safety, effectiveness, and quality of medications used in society. These acts serve as a foundation for pharmacy practice, public health, and patient protection.

Why Drug Acts Were Introduced?

To protect the public from unsafe, contaminated, or mislabeled drugs.
To regulate how drugs are tested, manufactured, marketed, and dispensed.
To ensure ethical pharmaceutical practices across the healthcare system.
To control drug abuse and manage addictive substances through proper classification.

Why Amendments Are Made?

Adapt to scientific progress (e.g., new drug types, gene therapy, biologics).
Address emerging health concerns (e.g., opioid crisis, counterfeit drugs).
Improve safety regulations and tighten standards after incidents or loopholes.
Keep up with modern pharmacy practice and technology (e.g., electronic prescribing, track-and-trace systems).

Benefits of Drug Acts to Society?

Safer medications: Ensure that drugs go through rigorous testing for safety and efficacy before they reach patients.
Quality assurance: Prevent harmful, fake, or substandard products from entering the supply chain.
Patient protection: Improve access to correct information, protect privacy, and ensure proper counseling.
Ethical pharmacy practice: Promote accountability among drug manufacturers, healthcare providers, and pharmacists.
Controlled substance management: Help reduce drug misuse and addiction while ensuring patients still receive needed treatments.

Top 200 Brand Generics

Compounding & Lab
Bonus Study Material

Email Us

help@practicequestions.com

Do you have more questions?

Read our

FAQ

Act Name	Year	Purpose / Importance
Pure Food and Drug Act	1906	Prohibited interstate commerce of misbranded and adulterated drugs and foods.
Federal Food, Drug, and Cosmetic Act (FDCA)	1938	Required drug safety testing before marketing; established the FDA.
Durham-Humphrey Amendment	1951	Created a distinction between prescription (Rx) and over-the-counter (OTC) drugs.
Kefauver-Harris Amendment	1962	Required proof of drug efficacy and safety before approval; added informed consent.
Controlled Substances Act (CSA)	1970	Established schedules for controlled substances; created DEA for enforcement.
Poison Prevention Packaging Act	1970	Required child-resistant packaging for certain medications.
Drug Listing Act	1972	Required drugs to have a unique National Drug Code (NDC).
Medical Device Amendments	1976	Regulated medical devices and required premarket approval and classification.
Orphan Drug Act	1983	Provided incentives for drug development for rare diseases.
Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act)	1984	Allowed generic drug approval via ANDA; extended patent life of brand drugs.
Prescription Drug Marketing Act (PDMA)	1987	Regulated drug samples and re-importation of drugs; restricted counterfeit drugs.
Anabolic Steroid Control Act	1990	Placed anabolic steroids under Schedule III controlled substances.
Omnibus Budget Reconciliation Act (OBRA-90)	1990	Required pharmacists to perform DUR and counsel Medicaid patients.
Dietary Supplement Health and Education Act (DSHEA)	1994	Allowed marketing of dietary supplements without FDA approval, unless unsafe.
Health Insurance Portability and Accountability Act (HIPAA)	1996	Protected patient health information and privacy.
FDA Modernization Act	1997	Streamlined drug approval, increased patient access to experimental drugs.
Combat Methamphetamine Epidemic Act	2005	Regulated OTC sales of pseudoephedrine and related substances.
Drug Quality and Security Act (DQSA)	2013	Improved drug compounding standards and drug supply chain security.
Comprehensive Addiction and Recovery Act (CARA)	2016	Expanded access to opioid addiction treatment and naloxone distribution.

Pre-1960s: Focus on basic safety and defining Rx vs. OTC drugs.
1970s–1990s: War on Drugs (strict enforcement) + generic drug access.
2000s–Present: Opioid crisis response, drug pricing reforms, and modernization.

Pure Food and Drug Act (1906)

First major U.S. drug law – Prohibited misbranded and adulterated drugs.
No safety testing requirement – Only addressed labeling, not efficacy or safety.
Led to FDA’s creation – Laid groundwork for future drug regulations.
Read more

Federal Food, Drug, and Cosmetic Act (FDCA, 1938)

Mandated safety testing – After the 1937 sulfanilamide tragedy (100+ deaths).
Established FDA approval process – Drugs must now be proven safe before sale.
Expanded to cosmetics & devices – Beyond just drugs and food.
FDA.gov

Durham Humphrey Amendment (1951)

Created Rx vs. OTC distinction – Defined which drugs require a prescription.
“Required label “Caution: Federal law prohibits dispensing without prescription.”
Allowed oral prescriptions – Made prescribing more flexible.
PDF copy

Kefauver Harris Amendment (1962)

Added efficacy requirement – Drugs must now be safe and effective.
Introduced clinical trial standards – Rigorous testing for FDA approval.
Mandated informed consent in clinical trials.
GMP requirements – Ensured manufacturing quality (Good Manufacturing Practices).
Triggered by the thalidomide tragedy.

Controlled Substances Act (CSA, 1970)

Created drug schedules (I-V) – Classified drugs by abuse potential (e.g., heroin = Schedule I).
Established DEA enforcement – Strict rules for prescribing/dispensing controlled substances.
Pharmacy record-keeping – Required logs for narcotics.
Central law for narcotic and controlled substance handling.
Click here (CSA, A Legal Overview for the 119th Congress)

Poison Prevention Packaging Act (1970)

Child-resistant packaging – Required for most Rx & OTC drugs.
Reduced accidental poisonings – Saved thousands of children’s lives.
Exceptions allowed (e.g., for elderly patients).
Click here for more information.

Drug Listing Act (1972)

Required each drug to have a unique NDC number.
Helped FDA track manufacturing and distribution.
FDA.gov

Medical Device Amendments (1976)

Classified medical devices into three classes based on risk.
Required premarket approval for high-risk devices.
GOVinfo.gov

Orphan Drug Act (1983)

Offered tax credits, exclusivity, and grants.
Incentivized drug development for rare diseases.
Encouraged Rare Disease Treatments – Provided financial incentives (tax credits, grants, 7-year market exclusivity)
Spurred Medical Innovation – Before 1983, only 38 orphan drugs existed; today, over 600+ have been approved
Improved Patient Access – Reduced costs for drugmakers, leading to life-saving therapies for previously ignored conditions, benefiting millions of rare-disease patients.
Read the full Act here

Hatch-Waxman Act (1984)

Drug Price Competition and Patent Term Restoration Act
Allowed generic drugs via Abbreviated New Drug Application (ANDA).
Balanced patent protection with generic competition.
GOVinfo.gov PDF

Prescription Drug Marketing Act (1987)

Banned Drug Diversion – Prohibited reimportation and resale of prescription drugs to prevent counterfeit or unsafe medications.
Restricted Samples – Required strict documentation for drug samples given to healthcare providers.
Protected Supply Chain
Helped prevent counterfeit drugs in the market.
FDA.gov

Anabolic Steroid Control Act (1990)

Classified anabolic steroids as Schedule III controlled substances.
Aimed at preventing abuse in sports and bodybuilding.
Read the Law here

OBRA-90 (1990) – Omnibus Budget Reconciliation Act

Mandated Patient Counseling – Required pharmacists to offer medication counseling to Medicaid patients.
Drug Utilization Review (DUR) – Introduced checks for interactions, overuse, and appropriate therapy.
Improved Outcomes – Aimed to reduce errors, boost adherence, and cut healthcare costs through education.
H.R. 5835 Public Law 101-508 101st Congress

Dietary Supplement Health and Education Act (DSHEA) 1994

Defined Supplements as Food, Not Drugs – Limited FDA oversight; no pre-market approval required.
Allowed “Structure/Function” Claims – Labels can describe general health benefits (e.g., “supports immunity”) but cannot claim to treat diseases.
Shifted Burden to FDA for Safety Proof – Manufacturers don’t need to prove safety; FDA must show harm to take action.
Public Law 103-417 103rd Congress

HIPAA (1996) – Health Insurance Portability and Accountability Act

Patient Privacy Protection – Establishes strict rules for safeguarding protected health information (PHI).
Security Rule – Requires healthcare providers to implement electronic data safeguards (encryption, access controls).
Portability – Ensures workers don’t lose health coverage when changing jobs.
Breach Notification – Mandates reporting of data breaches affecting 500+ patients.
Penalties for Violations – Fines up to $1.5 million/year for non-compliance.
PUBLIC LAW 104-191 104th Congress

FDA Modernization Act (FDAMA) 1997

Streamlined drug approvals – Accelerated review process for life-saving drugs.
Allowed direct-to-consumer (DTC) ads – Increased patient awareness of prescription drugs.
Promoted pediatric studies – Required better dosing data for children’s medications.
Encouraged off-label use disclosures and fast-track drugs.
Encouraged pediatric studies – Better dosing for children
Public Law 105–115 105th Congress

Combat Methamphetamine Epidemic Act (2005)

Restricted OTC Sales – Limited purchases of pseudoephedrine (a meth precursor) by requiring ID, sales logs, and monthly purchase limits.
Pharmacy Compliance – Mandated that pharmacies keep these products behind the counter and report suspicious bulk buying.
Reduced Meth Labs – Significantly decreased domestic meth production by cutting access to key ingredients.

Impact: Disrupted illegal meth manufacturing while maintaining legitimate cold/allergy medication access.

Drug Quality and Security Act (DQSA) (2013)

Regulated Compounding Pharmacies – Introduced stricter oversight after the 2012 fungal meningitis outbreak linked to contaminated steroid injections.
Track-and-Trace System – Enhanced drug supply chain security by requiring electronic tracking to prevent counterfeit drugs.
Two-Tier System – Differentiated traditional pharmacies from “outsourcing facilities” (large-scale compounders) with FDA registration and inspections.
H.R.3204 – 113th Congress

CARA (2016) Comprehensive Addiction and Recovery Act

Opioid Crisis Response – Expanded addiction treatment and prevention programs to combat the opioid epidemic.
Naloxone Access – Increased availability of naloxone (opioid overdose reversal drug) to first responders and communities.
Recovery Support – Funded grants for medication-assisted treatment (MAT) and recovery services for addicts.
July 22, 2016 Public Law 114-198